CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Ranibizumab

Last Updated: September 14, 2011
Result type: Reports
Project Number: S0253
Product Line: Common Drug Review

Generic Name: Ranibizumab

Brand Name: Lucentis

Manufacturer: Novartis Pharmaceuticals Canada Inc.

Indications: Macular edema, diabetic

Submission Type: New

Project Status: Complete

Date Recommendation Issued: March 19, 2012

Recommendation Type: List with clinical criteria and/or conditions